GPR114 Antibody

What is GPR114 and why is it significant in research?

GPR114, officially designated as Adhesion G protein-coupled receptor G5 (ADGRG5), is a member of the G-protein coupled receptor 2 family within the Adhesion G-protein coupled receptor (ADGR) subfamily. This 570 amino acid protein (approximately 63 kDa) is a membrane-associated receptor primarily expressed in immune cells, including human eosinophils, lymphocytes, and monocytes/macrophages . Its significance stems from its exclusive coupling to Gs proteins and involvement in cAMP signaling pathways related to immune cell function, particularly eosinophil migration, chemotaxis, and degranulation . Recent research has also linked GPR114 mutations to Leber's hereditary optic neuropathy, expanding its potential research applications .

What types of GPR114 antibodies are currently available for research?

Current commercially available GPR114 antibodies are predominantly rabbit polyclonal antibodies, though some mouse-derived options exist . These antibodies are generally characterized by:

• Reactivity: Primarily human GPR114, with some cross-reactivity to mouse

• Applications: Western blotting (WB), ELISA, immunofluorescence (IF), and immunohistochemistry (IHC)

• Format: Most are unconjugated, though conjugated versions (biotin, FITC, HRP, Alexa dyes) are available from select vendors

• Immunogen targets: Various regions including amino acids 91-140 and middle regions of the GPR114 protein

How should I determine the optimal GPR114 antibody for my specific research application?

Selection of the appropriate GPR114 antibody requires consideration of several experimental factors:

• Target species: Verify reactivity with your experimental model (predominantly human, with some antibodies showing mouse reactivity)

• Application compatibility: Confirm the antibody has been validated for your intended application (WB, ELISA, IHC, IF)

• Epitope location: Consider whether your research question requires detection of specific domains:

  • N-terminal fragment (NTF) detection requires antibodies targeting regions before the GPS cleavage site

  • C-terminal fragment (CTF) detection requires antibodies directed against regions after the cleavage site

• Cleavage status sensitivity: Some antibodies may preferentially detect cleaved versus uncleaved forms, which is critical for mechanistic studies

• Validation data: Review available images showing antibody performance in contexts similar to your experimental system

What are the recommended protocols for detecting GPR114 by Western blotting?

Optimal Western blotting for GPR114 detection requires specific methodological considerations:

• Sample preparation:

  • For membrane protein isolation, use buffers containing 1% NP-40 or similar non-ionic detergents

  • Consider PNGaseF treatment to remove glycosylation, which can improve band resolution and interpretation

• Gel electrophoresis parameters:

  • 8-10% SDS-PAGE is recommended for optimal resolution of the full-length protein (~90 kDa glycosylated form)

  • 12-15% gels may be preferable when analyzing cleaved fragments (NTF ~36 kDa)

• Antibody dilutions:

  • Primary antibody: 1:500-1:2000 dilution is typically recommended

  • Secondary antibody: 1:5000-1:10000 HRP-conjugated anti-rabbit IgG

• Expected banding patterns:

  • Full-length uncleaved GPR114: ~90 kDa (glycosylated)

  • N-terminal fragment (NTF): ~36 kDa

  • C-terminal fragment (CTF): May show variable molecular weight due to glycosylation

• Controls:

  • Positive control: EoL-1 cell lysate (eosinophilic-like cancer cell line with endogenous GPR114 expression)

  • Negative control: GPR114 knockdown lysates or non-expressing cell lines

What methodological approaches can verify GPR114 antibody specificity?

Verifying GPR114 antibody specificity requires multiple complementary approaches:

• Genetic validation:

  • siRNA/shRNA knockdown of GPR114 in expressing cells should reduce signal intensity

  • CRISPR/Cas9 knockout provides more definitive validation

  • Overexpression of tagged GPR114 (FLAG-tag, GFP-tag) allows comparison with antibody detection

• Peptide competition assays:

  • Pre-incubation of antibody with immunogen peptide should abolish specific signals

• Multiple antibody validation:

  • Compare staining/banding patterns using antibodies targeting different GPR114 epitopes

  • Consistent patterns across antibodies increase confidence in specificity

• Multi-application concordance:

  • Consistent results across Western blot, IHC, and IF applications support antibody specificity

  • Subcellular localization in IF should match expected membrane distribution

• Receptor mutant analysis:

  • Analysis of GPR114 GPS-cleavage deficient mutants (H225S) can confirm antibody ability to discriminate between cleaved and uncleaved forms

How can GPR114 cleavage status be accurately assessed using antibodies?

Assessment of GPR114 cleavage status requires specialized experimental approaches:

• Dual epitope-tagging strategy:

  • N-terminal tag (e.g., FLAG) and C-terminal tag (e.g., GFP-His) allow simultaneous tracking of both fragments

  • Western blotting with tag-specific antibodies enables quantification of cleavage efficiency

• Domain-specific antibodies:

  • Antibodies targeting the N-terminal fragment versus the C-terminal fragment enable detection of cleaved products

  • Ratio analysis of uncleaved to cleaved products provides quantitative measure of cleavage efficiency

• PNGaseF treatment:

  • Removal of N-glycans enhances electrophoretic resolution

  • Allows more accurate quantification of cleaved versus uncleaved forms

• Urea solubilization assay:

  • Treatment with 7M urea releases NTF from membrane preparations

  • Comparison of soluble versus membrane fractions by Western blotting confirms peripheral association of NTF and provides evidence of cleavage

• Mutant comparisons:

  • Analysis of wild-type versus GPS cleavage-deficient mutant (H225S) provides reference for uncleaved forms

What are the methodological considerations for studying GPR114 signaling pathways?

Investigating GPR114 signaling requires specialized approaches due to its unique activation mechanism:

• G-protein coupling assessment:

  • Direct G-protein activation assays reveal GPR114's exclusive coupling to Gs (not Gq, Gi, or G13)

  • cAMP accumulation assays provide functional readout of Gs activation

• Tethered agonist (TA) studies:

  • Application of synthetic GPR114 TA peptidomimetics to cells expressing GPR114

  • Measurement of cAMP production using ELISA or FRET-based sensors

• Receptor fragment dissociation experiments:

  • Urea treatment (7M) dissociates NTF from cleaved receptors

  • Comparison of signaling before and after NTF dissociation reveals tethered agonism mechanisms

• Chimeric receptor approaches:

  • PAR1-GPR114 chimeric receptors allow acute thrombin treatment to decrypt the tethered agonist

  • Enables temporal control over receptor activation

• Receptor mutant analysis:

  • Tethered agonist mutants (P6 Leu and P7 Met to Ala mutations) maintain cleavage but abolish TA-mediated activation

  • Provides tools for distinguishing cleavage from activation

How can researchers investigate the mechanosensitive properties of GPR114?

Investigating the mechanosensitive properties of GPR114 requires specialized experimental designs:

• Isoform-specific expression:

  • Expression of full-length (Q230) versus ΔQ230 isoforms to assess mechanosensory function

  • Position 8 (Q230) serves as a critical connector between the N-terminal activation part and C-terminal orientation part

• Mechanical stimulation assays:

  • Application of controlled vibration forces to cells expressing different GPR114 isoforms

  • Measurement of downstream signaling (cAMP production) in response to mechanical stimulation

• GAIN domain mutation studies:

  • Structure-guided mutations within the GAIN domain to assess impact on mechanosensing

  • Homology modeling based on related receptors (GPR56) to guide mutation design

• Force-application techniques:

  • Magnetic twisting cytometry or atomic force microscopy to apply defined forces

  • Parallel measurement of signaling activation to correlate force with receptor response

• Cell-substrate interaction studies:

  • Culturing cells on substrates with defined mechanical properties

  • Assessing GPR114 activation states in response to substrate rigidity

How can researchers overcome common challenges in GPR114 immunodetection?

Several technical challenges can arise when working with GPR114 antibodies:

• High background in Western blots:

  • Increase blocking time/concentration (5% non-fat milk or BSA)

  • Optimize antibody dilution (test range between 1:500-1:2000)

  • Include 0.1% Tween-20 in washing buffers

  • Consider overnight primary antibody incubation at 4°C

• Multiple bands or unexpected molecular weights:

  • Treat samples with PNGaseF to remove glycosylation heterogeneity

  • Compare patterns with tagged GPR114 constructs to identify specific fragments

  • Differentiate between full-length (~90kDa) and cleaved forms (NTF ~36kDa, CTF variable)

• Weak signal intensity:

  • Enrich membrane proteins using appropriate fractionation methods

  • Use enhanced chemiluminescence (ECL) substrates with higher sensitivity

  • Consider using epitope-tagged constructs for enhanced detection sensitivity

• Poor reproducibility:

  • Standardize lysate preparation methodology (consistent detergent concentration)

  • Ensure consistent storage conditions (-20°C, avoid freeze-thaw cycles)

  • Aliquot antibodies to prevent repeated freeze-thaw cycles

• Variability in immunofluorescence patterns:

  • Optimize fixation protocol (4% paraformaldehyde typically works well)

  • Consider membrane permeabilization conditions (0.1% Triton X-100 for 10 minutes)

  • Use confocal microscopy to better resolve membrane localization

What controls should be included when studying naturally occurring GPR114 variants or mutants?

When investigating GPR114 variants or mutants, multiple controls are essential:

• Expression level controls:

  • Quantitative PCR to normalize for transcript abundance

  • Total protein loading controls to ensure comparable expression levels

  • Surface biotinylation to confirm membrane localization

• Reference constructs:

  • Wild-type GPR114 as positive control

  • GPS cleavage-deficient mutant (H225S) as reference for uncleaved receptor

  • Tethered agonist mutants (P6L/P7M) as functional controls

• Domain-specific controls:

  • GPR114 constructs with specific domain deletions

  • Chimeric constructs with domains from related receptors (GPR56)

• Signaling pathway validation:

  • Direct G-protein activation assays to confirm Gs coupling specificity

  • Positive controls for signaling assays (GPR110-7TM for Gq, M2 muscarinic receptor for Gi, GPR56-7TM for G13)

  • cAMP accumulation assays with forskolin as positive control

• Isoform comparisons:

  • Parallel analysis of known isoforms (Q230 versus ΔQ230) for mechanosensory assessment

  • Species-specific isoform comparison (human versus mouse)

What cell models are most appropriate for studying endogenous GPR114 function?

Selection of appropriate cell models is critical for studying physiologically relevant GPR114 functions:

• Eosinophilic cell lines:

  • EoL-1 cells express endogenously cleaved GPR114 and respond to TA peptidomimetics

  • AML14.3D10 cells may also express GPR114

• Primary immune cells:

  • Human eosinophils isolated from peripheral blood

  • Mouse eosinophils from bone marrow cultures

  • Lymphocytes and monocytes/macrophages (human, rat, mouse)

• Heterologous expression systems:

  • HEK293 cells provide a clean background for signaling studies

  • CHO cells for stable expression and functional assays

• Tissue contexts:

  • Immune tissues (bone marrow, spleen, lymph nodes)

  • Consider tissues implicated in GPR114-associated disorders

• Comparative model systems:

  • Species-specific differences should be considered (human vs. mouse)

  • Tissue-specific expression patterns may vary between organisms

How does post-translational modification affect GPR114 antibody selection and experimental design?

Post-translational modifications of GPR114 significantly impact antibody selection and experimental approaches:

• Glycosylation considerations:

  • N-glycosylation sites affect apparent molecular weight

  • PNGaseF treatment may be necessary to obtain clear Western blot results

  • GPR114 CTF contains glycosylation sites not present in related receptors (e.g., GPR56)

• Proteolytic processing:

  • Self-cleavage at the GPS motif generates NTF (~36 kDa) and CTF fragments

  • Antibodies targeting regions spanning the cleavage site may show differential reactivity

  • Mutation of H225S creates cleavage-deficient controls

• Phosphorylation status:

  • Potential phosphorylation at intracellular loops may affect antibody binding

  • Phosphatase treatment can be used to assess phosphorylation impact

• Experimental timing:

  • Receptor processing kinetics should be considered when designing pulse-chase or temporal studies

  • Cleavage efficiency may vary with expression level and cell type

• Buffer composition:

  • Storage buffers containing glycerol (50%) and sodium azide (0.02%) help maintain antibody stability

  • Sample buffers should be optimized to maintain protein integrity

How can researchers investigate potential ligands for GPR114 using antibody-based approaches?

Identification and characterization of GPR114 ligands can be facilitated by antibody-based methods:

• Ligand-induced conformational change detection:

  • Conformation-specific antibodies that preferentially recognize active/inactive states

  • Antibody binding patterns before and after potential ligand application

• Proximity-based interaction assays:

  • Antibody-based pull-down of GPR114 followed by mass spectrometry

  • Proximity ligation assay (PLA) to detect potential interacting partners

• Receptor internalization studies:

  • Antibodies targeting extracellular epitopes to monitor surface expression

  • Flow cytometry or IF-based trafficking assays following ligand treatment

• Known ligand studies:

  • Use dihydromunduletone (antagonist) or 3-α-acetoxydihydrodeo-xygedunin (partial agonist) as reference compounds

  • Antibody detection of downstream signaling components (phospho-specific antibodies)

• Orphan receptor deorphanization strategies:

  • Screening libraries using antibody-based readouts of receptor activation

  • Cell-based reporter assays with antibody validation of expression

What methodological approaches can resolve contradictory findings regarding GPR114 cleavage status?

Resolving contradictory findings about GPR114 cleavage requires rigorous methodological approaches:

• Expression system comparisons:

  • Analyze GPR114 in multiple cell types (heterologous vs. endogenous)

  • Compare overexpression systems with endogenous levels

• Multiple detection methods:

  • Use both tag-based (FLAG, GFP) and antibody-based detection

  • Apply multiple antibodies targeting different epitopes

  • Combine biochemical fractionation with immunodetection

• Quantitative cleavage assessment:

  • Ratio analysis of uncleaved to cleaved products by densitometry

  • PNGaseF treatment to enhance electrophoretic resolution

• Mutation analysis:

  • Compare wild-type with GPS cleavage mutant (H225S)

  • Analyze domain truncation mutants to assess GAIN domain influence

• Functional correlation:

  • Link cleavage status to functional readouts (Gs activation, cAMP production)

  • Demonstrate cleavage-dependence of tethered agonism

How can researchers differentiate between mechanistic roles of GPR114 in different immune cell populations?

Distinguishing GPR114 functions across immune cell populations requires specialized approaches:

• Cell-specific expression profiling:

  • Quantitative PCR and Western blotting to compare expression levels

  • Single-cell RNA sequencing to identify cell subpopulations expressing GPR114

• Functional assays tailored to cell types:

  • Eosinophils: Chemotaxis, migration, degranulation assays

  • Lymphocytes: Proliferation, cytokine production

  • Monocytes/macrophages: Phagocytosis, inflammatory response

• Cell-specific knockout/knockdown:

  • CRISPR/Cas9 with cell-specific promoters

  • siRNA delivery to specific immune populations

• Receptor activity monitoring:

  • Phospho-specific antibodies to detect downstream signaling

  • FRET-based cAMP sensors to monitor real-time activation

• Isoform-specific function:

  • Analysis of cell-specific expression of Q230 versus ΔQ230 isoforms and correlation with mechanosensory function

  • Isoform-specific knockdown to determine relative contributions

What are the optimal storage conditions for maintaining GPR114 antibody performance?

Proper storage is critical for maintaining GPR114 antibody functionality:

• Temperature requirements:

  • Store at -20°C for long-term storage

  • Avoid repeated freeze-thaw cycles

  • For frequent use, small aliquots can be stored at 4°C for up to one month

• Buffer composition:

  • Typically supplied in PBS with 0.02% sodium azide and 50% glycerol (pH 7.3)

  • Some formulations may contain 0.1% BSA for additional stability

• Aliquoting strategy:

  • Divide into single-use aliquots upon receipt

  • Use sterile technique when handling to prevent contamination

• Stability considerations:

  • Most antibodies are stable for one year after shipment when properly stored

  • Monitor for signs of degradation (loss of activity, precipitation)

• Shipping conditions:

  • Typically shipped on blue ice or with cold packs

  • Check for any temperature exposure indicators upon receipt

What methodological approaches can extend antibody shelf-life while maintaining specificity?

Several approaches can help maintain antibody performance over extended periods:

• Stabilizing additives:

  • Addition of carrier proteins (BSA 0.1-1%) can enhance stability

  • Glycerol (20-50%) prevents freeze-thaw damage and microbial growth

• Contamination prevention:

  • Use sterile technique when handling antibodies

  • Include sodium azide (0.02%) as antimicrobial agent

  • Filter solutions if necessary

• Physical handling:

  • Avoid vortexing (gentle mixing only)

  • Minimize exposure to light (especially for fluorophore-conjugated antibodies)

  • Centrifuge briefly before opening to collect solution at bottom of vial

• Quality control measures:

  • Regularly test antibody performance on reference samples

  • Document lot-to-lot variations

  • Consider antibody validation with orthogonal methods

• Alternative preservation methods:

  • Lyophilization for extremely long-term storage

  • Addition of trehalose or other cryoprotectants for freeze-drying